130 related articles for article (PubMed ID: 36396748)
21. A monoclonal antibody against basic fibroblast growth factor attenuates cisplatin resistance in lung cancer by suppressing the epithelial-mesenchymal transition.
Hu P; So K; Chen H; Lin Q; Xu M; Lin Y
Int J Immunopathol Pharmacol; 2022; 36():3946320221105134. PubMed ID: 35649742
[No Abstract] [Full Text] [Related]
22. MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells.
Li H; Zhang P; Sun X; Sun Y; Shi C; Liu H; Liu X
Int J Oncol; 2015 Oct; 47(4):1379-92. PubMed ID: 26323677
[TBL] [Abstract][Full Text] [Related]
23. MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating G₁/S transition and apoptosis by targeting p21(WAF1/CIP1).
Wang H; Zhu LJ; Yang YC; Wang ZX; Wang R
Br J Cancer; 2014 Jul; 111(2):339-54. PubMed ID: 24921914
[TBL] [Abstract][Full Text] [Related]
24. Epithelial-mesenchymal transition is necessary for acquired resistance to cisplatin and increases the metastatic potential of nasopharyngeal carcinoma cells.
Zhang P; Liu H; Xia F; Zhang QW; Zhang YY; Zhao Q; Chao ZH; Jiang ZW; Jiang CC
Int J Mol Med; 2014 Jan; 33(1):151-9. PubMed ID: 24173500
[TBL] [Abstract][Full Text] [Related]
25. Depleted aldehyde dehydrogenase 1A1 (ALDH1A1) reverses cisplatin resistance of human lung adenocarcinoma cell A549/DDP.
Wei Y; Wu S; Xu W; Liang Y; Li Y; Zhao W; Wu J
Thorac Cancer; 2017 Jan; 8(1):26-32. PubMed ID: 27813328
[TBL] [Abstract][Full Text] [Related]
26. COX-2 potentiates cisplatin resistance of non-small cell lung cancer cells by promoting EMT in an AKT signaling pathway-dependent manner.
Jiang GB; Fang HY; Tao DY; Chen XP; Cao FL
Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3838-3846. PubMed ID: 31115011
[TBL] [Abstract][Full Text] [Related]
27. [Epithelial-mesenchymal transition (EMT) and its effect on microRNA expression in lung cancer].
Wang HB; Zhang HJ; Su JM; Zhou WY; Wang HY; Chen XF
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):590-3. PubMed ID: 22325218
[TBL] [Abstract][Full Text] [Related]
28. Silence of lncRNA UCA1 rescues drug resistance of cisplatin to non-small-cell lung cancer cells.
Liu X; Huang Z; Qian W; Zhang Q; Sun J
J Cell Biochem; 2019 Jun; 120(6):9243-9249. PubMed ID: 30652341
[TBL] [Abstract][Full Text] [Related]
29. N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell lines.
Zhang X; Liu G; Kang Y; Dong Z; Qian Q; Ma X
PLoS One; 2013; 8(3):e57692. PubMed ID: 23520479
[TBL] [Abstract][Full Text] [Related]
30. Elevated TRIM23 expression predicts cisplatin resistance in lung adenocarcinoma.
Zhang Y; Du H; Li Y; Yuan Y; Chen B; Sun S
Cancer Sci; 2020 Feb; 111(2):637-646. PubMed ID: 31677335
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-106a-5p alleviated the resistance of cisplatin in lung cancer cells by targeting Jumonji domain containing 6.
Ge X; Jiang Y; Hu X; Yu X
Transpl Immunol; 2021 Dec; 69():101478. PubMed ID: 34607003
[TBL] [Abstract][Full Text] [Related]
32. Asiatic Acid (AA) Sensitizes Multidrug-Resistant Human Lung Adenocarcinoma A549/DDP Cells to Cisplatin (DDP) via Downregulation of P-Glycoprotein (MDR1) and Its Targets.
Cheng Q; Liao M; Hu H; Li H; Wu L
Cell Physiol Biochem; 2018; 47(1):279-292. PubMed ID: 29768255
[TBL] [Abstract][Full Text] [Related]
33. Correlation of long non-coding RNA H19 expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma.
Wang Q; Cheng N; Li X; Pan H; Li C; Ren S; Su C; Cai W; Zhao C; Zhang L; Zhou C
Oncotarget; 2017 Jan; 8(2):2558-2567. PubMed ID: 27911863
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of epithelial-mesenchymal transition-related molecules in lung adenocarcinoma.
Zhang Y; Wang LF; Gao JH; Li L; Jiang P; Lv X; Yu LX; Yang J; Li RT; Liu BR
Curr Oncol; 2019 Apr; 26(2):e121-e127. PubMed ID: 31043817
[TBL] [Abstract][Full Text] [Related]
35. miR-324-3p reverses cisplatin resistance by inducing GPX4-mediated ferroptosis in lung adenocarcinoma cell line A549.
Deng SH; Wu DM; Li L; Liu T; Zhang T; Li J; Yu Y; He M; Zhao YY; Han R; Xu Y
Biochem Biophys Res Commun; 2021 Apr; 549():54-60. PubMed ID: 33662669
[TBL] [Abstract][Full Text] [Related]
36. [Increased expression of acetaldehyde dehydrogenase in cisplatin-resistant human lung adenocarcinoma A549/DDP cells].
He J; Song X; Yu L; Li J; Qiao Z; Jiu R; Yu B; Liu X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 May; 31(5):625-9. PubMed ID: 25940289
[TBL] [Abstract][Full Text] [Related]
37. Krüppel-Like Factor 4 Enhances Sensitivity of Cisplatin to Lung Cancer Cells and Inhibits Regulating Epithelial-to-Mesenchymal Transition.
Liu S; Yang H; Chen Y; He B; Chen Q
Oncol Res; 2016; 24(2):81-7. PubMed ID: 27296948
[TBL] [Abstract][Full Text] [Related]
38. Norcantharidin reverses cisplatin resistance and inhibits the epithelial mesenchymal transition of human non‑small lung cancer cells by regulating the YAP pathway.
Jin D; Wu Y; Shao C; Gao Y; Wang D; Guo J
Oncol Rep; 2018 Aug; 40(2):609-620. PubMed ID: 29901163
[TBL] [Abstract][Full Text] [Related]
39. Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells.
Han ML; Zhao YF; Tan CH; Xiong YJ; Wang WJ; Wu F; Fei Y; Wang L; Liang ZQ
Acta Pharmacol Sin; 2016 Dec; 37(12):1606-1622. PubMed ID: 27840408
[TBL] [Abstract][Full Text] [Related]
40. CircPVT1 contributes to chemotherapy resistance of lung adenocarcinoma through miR-145-5p/ABCC1 axis.
Zheng F; Xu R
Biomed Pharmacother; 2020 Apr; 124():109828. PubMed ID: 31986409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
